Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBT Margin (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed EBT Margin for 4 consecutive years, with 196.78% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 6238.0% to 196.78% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 241.25% through Dec 2025, down 14482.0% year-over-year, with the annual reading at 241.25% for FY2025, 14482.0% down from the prior year.
  • EBT Margin for Q4 2025 was 196.78% at bioAffinity Technologies, up from 349.08% in the prior quarter.
  • The five-year high for EBT Margin was 81.37% in Q1 2024, with the low at 427752.87% in Q3 2022.
  • Average EBT Margin over 4 years is 45472.06%, with a median of 317.59% recorded in 2025.
  • Peak annual rise in EBT Margin hit 42698613bps in 2023, while the deepest fall reached -205101bps in 2023.
  • Over 4 years, EBT Margin stood at 71380.39% in 2022, then skyrocketed by 100bps to 107.12% in 2023, then decreased by -25bps to 134.4% in 2024, then tumbled by -46bps to 196.78% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 196.78%, 349.08%, and 317.59% for Q4 2025, Q3 2025, and Q2 2025 respectively.